COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval

Key Points

Safety and efficacy of convalescent plasma have improved with better evidence quality over time, in response to COVID-19.
Increased regulatory approval requires robust randomized controlled trial data to support efficacy.
Analysis focuses on the roadmap for future infectious disease outbreaks and the role of convalescent plasma.
Highlights the urgency of conducting randomized controlled trials to validate convalescent plasma's effectiveness.

Abstract

With pandemic progression, the COVID-19 convalescent plasma safety and efficacy evidence quality increased. Ultimate regulatory approval required robust randomized control efficacy data. Future infectious disease outbreaks require randomized controlled trials in the convalescent plasma roadmap.

COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval

Key Points

Abstract

Cite This Study

Also Consider

Also Consider